myopathy

By Targets:	CCR (2) CD38 (1) Complement System (2) Dipeptidyl Peptidase (1) Dopamine Receptor (2) Dynamin (2) Endogenous Metabolite (8) PPAR (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (8) Inflammation/Immunology (6) Metabolic Disease (9) Neurological Disease (8)
Oligonucleotides:	Antisense Oligonucleotides (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113071A

Mevalonic acid lithium salt Maximum Cited Publications 9 Publications Verification MVA lithium salt	Endogenous Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .

HY-107855

DL-Mevalonolactone 1 Publications Verification (±)-Mevalonolactone; Mevalolactone	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

HY-P3502

Zilucoplan RA101495; RA3193	Complement System	Inflammation/Immunology
Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM) .

HY-132583A

IONIS-DNM2-2.5Rx sodium DYM101 sodium	Others Dynamin	Cardiovascular Disease
IONIS-DNM2-2.5Rx sodium is an antisense agent targeting dynamin 2, and has the potential for the research of centronuclear myopathy (CNM) .

HY-132583

IONIS-DNM2-2.5Rx DYM101	Dynamin Others	Cardiovascular Disease
IONIS-DNM2-2.5Rx (DYM101) is an antisense agent targeting dynamin 2. IONIS-DNM2-2.5Rx has the potential for the research of centronuclear myopathy (CNM) .

HY-113071

Mevalonic acid MVA	Endogenous Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .

HY-113071C

(S)-Mevalonic acid (S)-MVA	Endogenous Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease
(S)-Mevalonic acid is the isomer of Mevalonic acid (HY-113071). Mevalonic acid ((S)-DCIT) is a precursor substance of the mevalonate pathway，which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .

HY-113071AR

Mevalonic acid (lithium salt) (Standard)	Endogenous Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease
Mevalonic acid (lithium salt) (Standard) is the analytical standard of Mevalonic acid (lithium salt). This product is intended for research and analytical applications. Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .

HY-107855R

DL-Mevalonolactone (Standard)	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone (Standard) is the analytical standard of DL-Mevalonolactone. This product is intended for research and analytical applications. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

HY-P3502A

Zilucoplan TFA RA101495 TFA; RA3193 TFA	Complement System	Inflammation/Immunology
Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM) .

HY-P99466

Begelomab SAND-26	Dipeptidyl Peptidase	Inflammation/Immunology
Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy .

HY-156120

CD38 inhibitor 3	CD38	Metabolic Disease
CD38 inhibitor 3 (compound 1) is the orally active inhibitor for CD38 (IC₅₀=11 nM). CD38 inhibitor 3 increases intracellular NAD ⁺ levels, activates the Nrf2 signaling pathway, and promotes mitochondrial biogenesis. CD38 inhibitor 3 improves muscle function .

HY-112597A

Mavodelpar REN001; HPP593	PPAR	Inflammation/Immunology
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD) . Mavodelpar is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-103406A

PNU-177864 hydrochloride	Dopamine Receptor CCR	Neurological Disease
PNU-177864 is a potent, selective, orally active dopamine D₃ receptor antagonist. PNU-177864 induces phospholipid metabolism in vivo and has anti-schizophrenia activity .

HY-103406

PNU-177864	Dopamine Receptor CCR	Neurological Disease Metabolic Disease
PNU-177864 is a potent, selective, orally active dopamine D₃ receptor antagonist. PNU-177864 induces phospholipid metabolism in vivo and has anti-schizophrenia activity .

HY-134377

Bocidelpar ASP0367; MA-0211	PPAR	Metabolic Disease
Bocidelpar (ASP0367; MA-0211) is a selective, orally active PPARδ modulator. Bocidelpar activates the PPARδ downstream signaling pathway, upregulates the expression of target genes such as ABCA1 and ACAA2. Bocidelpar then promotes fatty acid oxidation (FAO) and mitochondrial biogenesis, and improves mitochondrial dysfunction. Bocidelpar can improve mitochondrial biogenesis and function in muscle cells. Bocidelpar is mainly used in the study of mitochondrial dysfunction diseases such as primary mitochondrial myopathy (PMM) and Duchenne muscular dystrophy (DMD) .

HY-128850R

N-Acetyl-D-mannosamine (Standard) N-Acetylmannosamine (Standard); ManNAc (Standard)	Endogenous Metabolite	Cardiovascular Disease Neurological Disease
N-Acetyl-D-mannosamine (Standard) is an analytical standard for N-Acetyl-D-mannosamine. This product is intended for research and analytical applications. N-Acetyl-D-mannosamine (ManNAc) is an orally active sialic acid (Sialic Acid) precursor that can prevent hypertension by increasing sialylation of IgG and has potential for use in cardiovascular disease research. N-Acetyl-D-mannosamine activates hypocretin (HCRT) gene expression and alters

HY-128850

N-Acetyl-D-mannosamine N-Acetylmannosamine; ManNAc	Endogenous Metabolite	Cardiovascular Disease Neurological Disease
N-Acetyl-D-mannosamine (ManNAc) is an oral active sialic acid precursor that can prevent hypertension by increasing sialylation of IgG, making it a promising candidate for cardiovascular disease research. Additionally, N-Acetyl-D-mannosamine can activate hypocretin (HCRT) gene expression in orexin neurons and improve neurodegeneration caused by aging, offering potential avenues for research in neurological disorders .

Cat. No.	Product Name

HY-L118

Sodium Channel Blocker Library	156 compounds
Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion. MCE offers a unique collection of 156 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.

Sodium Channel Blocker Library

156 compounds

Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion.

MCE offers a unique collection of 156 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.

HY-L007

Immunology/Inflammation Compound Library	6,370 compounds
The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation. MCE designs a unique collection of 6,370 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

Immunology/Inflammation Compound Library

6,370 compounds

The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.

MCE designs a unique collection of 6,370 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

Cat. No.	Product Name	Target	Research Area